The EXTREME regimen with the addition of the EGFR inhibitor cetuximab to platinum and fluorouracil resulted in a significant prolongation of OS in patients with R/M HNSCC [14]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.